Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Harrow Health ( (HROW) ).
On September 8, 2025, Harrow, Inc. entered into a purchase agreement with BTIG, LLC for the sale of $250 million in senior notes due 2030, with a 8.625% interest rate. The company completed the sale of these notes on September 12, 2025, receiving approximately $244 million in net proceeds. Harrow intends to use these funds to prepay existing borrowings, pay exit costs, and for general corporate purposes, including potential strategic business development opportunities. Additionally, Harrow announced the redemption of its 8.625% Senior Notes due 2026, scheduled for October 13, 2025, which will result in their delisting from Nasdaq.
The most recent analyst rating on (HROW) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.
Spark’s Take on HROW Stock
According to Spark, TipRanks’ AI Analyst, HROW is a Neutral.
Harrow Health’s overall stock score is driven by strong technical momentum and positive corporate events, offset by financial performance challenges and valuation concerns. The earnings call provided a positive outlook with strategic growth plans, but financial risks remain significant.
To see Spark’s full report on HROW stock, click here.
More about Harrow Health
Average Trading Volume: 503,686
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.46B
Find detailed analytics on HROW stock on TipRanks’ Stock Analysis page.